Robin Birus

Mr. Robin Birus

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2019 in Molecules
Verified
Journal Article
Open access
PDF file
SHSamer Haidar
Samer Haidar
DADagmar Aichele
Dagmar Aichele
RBRobin Birus
Robin Birus
JHJanine Hielscher
Janine Hielscher
TLTuomo Laitinen
Tuomo Laitinen
Joachim JoseJoachim Jose
Joachim Jose
Protein kinase CK2 is an emerging target for therapeutic intervention in human diseases, particularly in cancer. Inhibitors of this enzyme are currently in clinical trials, indicating the druggability of human CK2. By virtual screening of the ZINC database, we found that the natural compound bikaverin can fit well in the ATP binding site of the target enzyme CK2. By further in vitro evaluation using CK2 holoenzyme, bikaverin turned to be a potent inhibitor with an IC50 value of 1.24 µM. In this work, the cell permeability of bikaverin was determined using a Caco-2 cell permeability assay as a prerequisite for cellular evaluation and the compound turned out to be cell permeable with a Papp- value of 4.46 × 10−6 cm/s. Bikaverin was tested for its effect on cell viability using a MTT assay and cell proliferation using an EdU assay in different cancer cell lines (MCF7, A427 and A431 cells). Cell viability and cell proliferation were reduced dramatically after treatment with 10 µM bikaverin for 24 h. Additionally the IncuCyte® live-cell imaging system was applied for monitoring the cytotoxicity of bikaverin in the three tested cancer cell lines. Finally, molecular dynamic studies were performed to clarify the ligand binding mode of bikaverin at the ATP binding site of CK2 and to identify the amino acids involved.

13 December 2017 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JHJennifer Hochscherf
Jennifer Hochscherf
DLDirk Lindenblatt
Dirk Lindenblatt
BWBenedict Witulski
Benedict Witulski
RBRobin Birus
Robin Birus
DADagmar Aichele
Dagmar Aichele
Karsten NiefindKarsten Niefind
Karsten Niefind
Protein kinase CK2, a member of the eukaryotic protein kinase superfamily, is associated with cancer and other human pathologies and thus an attractive drug target. The indeno[1,2-b]indole scaffold is a novel lead structure to develop ATP-competitive CK2 inhibitors. Some indeno[1,2-b]indole-based CK2 inhibitors additionally obstruct ABCG2, an ABC half transporter overexpressed in breast cancer and co-responsible for drug efflux and resistance. Comprehensive derivatization studies revealed substitutions of the indeno[1,2-b]indole framework that boost either the CK2 or the ABCG2 selectivity or even support the dual inhibition potential. The best indeno[1,2-b]indole-based CK2 inhibitor described yet (IC50 = 25 nM) is 5-isopropyl-4-(3-methylbut-2-enyl-oxy)-5,6,7,8-tetrahydroindeno[1,2-b]indole-9,10-dione (4p). Herein, we demonstrate the membrane permeability of 4p and describe co-crystal structures of 4p with CK2α and CK2α′, the paralogs of human CK2 catalytic subunit. As expected, 4p occupies the narrow, hydrophobic ATP site of CK2α/CK2α′, but surprisingly with a unique orientation: its hydrophobic substituents point towards the solvent while its two oxo groups are hydrogen-bonded to a hidden water molecule. An equivalent water molecule was found in many CK2α structures, but never as a critical mediator of ligand binding. This unexpected binding mode is independent of the interdomain hinge/helix αD region conformation and of the salt content in the crystallization medium.

5 June 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
EEEhab El-Awaad
Ehab El-Awaad
RBRobin Birus
Robin Birus
CMChristelle Marminon
Christelle Marminon
ZBZouhair Bouaziz
Zouhair Bouaziz
LBLaurens Ballentin
Laurens Ballentin
Joachim JoseJoachim Jose
Joachim Jose
Protein kinase CK2 is involved in regulating cellular processes, such as cell cycle, proliferation, migration, and apoptosis, making it an attractive anticancer target. We previously described a prenyloxy-substituted indeno[1,2-b]indole (5-isopropyl-4-(3-methylbut-2-enyloxy)-5,6,7,8-tetrahydroindeno[1,2-b]indole-9,10-dione (4p)) as a very potent inhibitor of CK2 holoenzyme (IC50 = 25 nM). Here, we report the broad-spectrum anticancer activity of 4p and provide substantial progress on its pharmacokinetic properties. Using a cell-based CK2 activity assay and live-cell imaging of cultured A431, A549, and LNCaP cancer cell lines, cellular CK2 target engagement was shown as well as strong antiproliferative, anti-migratory and apoptosis-inducing effects of 4p. Furthermore, evidence was found for the ability of 4p to disrupt A549 spheroid cohesion. A series of LC-MS/MS experiments revealed high and rapid cellular uptake (intracellular concentration is approximately 5 µM after 1 h incubation) and low metabolic stability of 4p. These results point to the value of 4p as a potent CK2 inhibitor with promising anticancer activities and should trigger future medicinal chemistry efforts to improve the drug-like properties of this compound.

6 December 2021 in FEBS Open Bio
Verified
Journal Article
Open access
PDF file
RBRobin Birus
Robin Birus
EEEhab El-Awaad
Ehab El-Awaad
LBLaurens Ballentin
Laurens Ballentin
FAFaten Alchab
Faten Alchab
DADagmar Aichele
Dagmar Aichele
Joachim JoseJoachim Jose
Joachim Jose
Highly pleiotropic and constitutively active protein kinase CK2 is a key target in cancer therapy, but only one small‐molecule inhibitor has reached clinical trials—CX‐4945. In this study, we present the indeno[1,2‐b]indole derivative 5‐isopropyl‐4‐methoxy‐7‐methyl‐5,6,7,8‐tetrahydroindeno[1,2‐b]indole‐9,10‐dione (5a‐2) that decreased the intracellular CK2 activity in A431, A549, and LNCaP tumor cell lines analogous to CX‐4945 (> 75% inhibition at 20 µm) and similarly blocked CK2‐specific Akt phosphorylation in LNCaP cells. Cellular uptake analysis demonstrated higher intracellular concentrations of 5a‐2 (408.3 nm) compared with CX‐4945 (119.3 nm). This finding clarifies the comparable effects of both compounds on the intracellular CK2 activity despite their different inhibitory potency in vitro [IC50 = 25 nm (5a‐2) and 3.7 nm (CX‐4945)]. Examination of the effects of both CK2 inhibitors on cancer cells using live‐cell imaging revealed notable differences. Whereas CX‐4945 showed a stronger pro‐apoptotic effect on tumor cells, 5a‐2 was more effective in inhibiting tumor cell migration. Our results showed that 49% of intracellular CX‐4945 was localized in the nuclear fraction, whereas 71% of 5a‐2 was detectable in the cytoplasm. The different subcellular distribution, and thus the site of CK2 inhibition, provides a possible explanation for the different cellular effects. Our study indicates that investigating CK2 inhibition‐mediated cellular effects in relation to the subcellular sites of CK2 inhibition may help to improve our understanding of the preferential roles of CK2 within different cancer cell compartments.

30 October 2019
Verified
Conference Paper
Open access
RBRobin Birus
Robin Birus
Marc Le BorgneMarc Le Borgne
Marc Le Borgne
Joachim JoseJoachim Jose
Joachim Jose
The highly pleiotropic and constitutively active protein kinase CK2 plays an important role in several cellular mechanisms. Due to its overexpression and elevated activity in tumor cells, CK2 became an important target in tumor therapy nowadays. It was shown, that the kinase causes antiapoptotic and proliferation enhancing effects in neoplastic tissues [1,2]. Moreover, the reduction of CK2 activity in tumor cells leads to apoptosis while normal cells stay unaffected [3]. Indeno[1,2-b]indoles are ATP competitive CK2 inhibitors with IC50 values in the nanomolar range of concentration. NA16 was described as one of the most potent indeno[1,2-b]indoles with an IC50 value of 25 nM [4]. Therefore, the pharmacokinetic properties of NA16 were further analyzed during this study. It could be shown that NA16 reduced the growth of different tumor cell lines and induced cancer cell apoptosis. Furthermore, its effect on HUVEC cell growth was comparable with the effect of CX-4945, a CK2 inhibitor in clinical trials [5], which was used as control. Intracellular concentrations of NA16 were higher than concentrations of CX-4945 at different time points. Metabolism studies showed that NA16 is moderate metabolic stable and is not glucuronidated. These results underline the potential of NA16 as an antitumor drug. References: [1] Ahmed, K et al.: Trends Cell Biol 2002, 12, 226-230.[2] Meggio, F. and Pinna, L.A.: FASEB J. 2003, 17, 349-368.[3] Slaton, J. W. et al.: Mol Cancer Res 2004, 2, 172.[4] Gozzi, G. J. et al.: J Med Chem 2015, 58, 265-277.[5] Siddiqui-Jain, A. et al.: Cancer Res 2010, 70, 24.